Where is Dimedi located?

Dimedi is headquartered in United Kingdom.

Is Dimedi a funded company?

Dimedi is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Dimedi rank among its competitors?

Dimedi ranks 4204th amongst 4311 active competitors, of which 117 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Ipsen, which secured $618K in Dec, 2023.

Who are the top competitors of Dimedi?

Dimedi's top competitors include Abbott, WuXi AppTec and ANI Pharmaceuticals. Among them, Ipsen secured the most recent funding round in December, 2023.

Dimedi - 2026 Company Profile & Competitors

Most viewed in 2019

Dimedi is an unfunded company based in United Kingdom. Dimedi has not raised any funding yet. The company has 4311 active competitors, including 117 funded and 328 that have exited. Its top competitors include companies like Abbott, WuXi AppTec and ANI Pharmaceuticals.

Key Metrics

Location

United Kingdom

Stage

Unfunded

Ranked

4204^th among 4311 active competitors

Similar Companies

Abbott & 3518 more

View Dimedi's full profile

Dimedi has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Dimedi include Abbott, WuXi AppTec and ANI Pharmaceuticals. Here is the list of Top 10 competitors of Dimedi, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Abbott 1888, Libertyville (United States), Public	Developer of medical devices, generic pharmaceuticals, and nutrition products	-	Digital Pharma Lab, Castle Investment Management ... & 10 others	80/100
2nd	WuXi AppTec 2000, Shanghai (China), Public	Provider of CRO and CDMO services	$40M	Synergis Capital, HongShan & 27 others	79/100
3rd	ANI Pharmaceuticals 1996, Baudette (United States), Public	Manufacturer of pharmaceutical products, including extended-release capsules and immediate-release tablets	-	Ampersand Capital, US Bank & 4 others	64/100
4th	EVERSANA 2014, Milwaukee (United States), Funding Raised	Provider of consulting services for drug pricing access, reimbursement, and regulatory support	-	ACE & Company, North Sky Capital & 2 others	63/100
5th	Aptar 1992, Crystal Lake (United States), Public	Provider of regulatory support, brand differentiation, and prototyping services	-	Al Zayani Investments	63/100
6th	Neolife 1958, Fremont (United States), Unfunded	Provider of whole food nutritional supplements	-	-	63/100
7th	Ipsen 1929, Paris (France), Public	Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes	-	Digital Pharma Lab, PAI Partners & 2 others	62/100
8th	Zuellig Pharma 1992, Singapore (Singapore), Funding Raised	Provider of clinical research, quality management, logistics, and clinical trial supply services	-	Temasek	61/100
9th	Eurofins Scientific 1987, Luxembourg (Luxembourg), Public	Provider of laboratory testing services and CRO contract research services	-	CDPQ, Holland Capital & 1 others	61/100
10th	Precision Medicine Group 2012, Bethesda (United States), Late Stage	Provider of clinical research, development, and commercialization services for life sciences	$532M	TPG, Blackstone & 7 others	60/100
4204th	Dimedi United Kingdom, Unfunded	-	-	-	16/100